NCT05540873 - A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

April 30, 2024

Conditions

Recurrent Malignant Glioma

Interventions

DRUG

YYB-103

Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center, Korea, Goyang-si